Saturday’s Midday Stock Update: Clovis Oncology (CLVS), Inovio Pharmaceuticals (INO), Ventas (VTR), Recro Pharma (REPH), Continental Resources (CLR)

So far Saturday, March 28, NASDAQ is down -1.28% and the S&P is up 0.15%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Clovis Oncology (CLVSResearch Report), Inovio Pharmaceuticals (INOResearch Report), Ventas (VTRResearch Report), Recro Pharma (REPHResearch Report) and Continental Resources (CLRResearch Report).

Clovis Oncology is up 34.53% in midday trading to $7.13. Shares opened today at $5.30. The company has a 52-week low of $2.93 and a 52-week high of $25.88. On the Street’s front, the average 12-month analyst price target for the stock is $18.00, marking a 239.62% potential upside from current levels. In a report issued on February 25, H.C. Wainwright analyst Edward White reiterated a Buy rating on CLVS, with a price target of $27.00, which represents a potential upside of 409% from where the stock is currently trading. Separately, on February 24, J.P. Morgan’s Cory Kasimov maintained a Hold rating on the stock . In the last 30 days, insiders purchased $27.9K worth of CLVS shares.

Inovio Pharmaceuticals is up 14.44% in midday trading to $8.32. Shares opened today at $7.27. The company has a 52-week low of $1.92 and a 52-week high of $19.36. On the Street’s front, the average 12-month analyst price target for the stock is $10.00, marking a 37.55% potential upside from current levels. In a report released yesterday, Maxim Group analyst Jason McCarthy assigned a Buy rating on INO, with a price target of $12.00, which represents a potential upside of 65% from where the stock is currently trading. Separately, on March 13, RBC’s Gregory Renza downgraded the stock to Hold and has a price target of $7.00. In the last 30 days, insiders purchased $1.44M worth of INO shares. Over the last 3 months, the insider sentiment on Inovio Pharmaceuticals has been positive based on 24 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Ventas is up 10.87% in midday trading to $30.39. Shares opened today at $27.41. The company has a 52-week low of $13.35 and a 52-week high of $75.40. On the Street’s front, the average 12-month analyst price target for the stock is $44.33, marking a 61.73% potential upside from current levels. In a report released yesterday, Wells Fargo analyst Todd Stender maintained a Sell rating on VTR, with a price target of $29.00, which implies an upside of 6% from current levels. Separately, on March 25, Raymond James’ Jonathan Hughes upgraded the stock to Buy and has a price target of $45.00.

See today’s analyst top recommended stocks >>

Recro Pharma is down -10.63% in midday trading to $6.64. Shares opened today at $7.43. The company has a 52-week low of $5.74 and a 52-week high of $19.21. On the Street’s front, the average 12-month analyst price target for the stock is $18.00, marking a 142.26% potential upside from current levels. In a report issued on March 5, Stephens Inc analyst Jacob Johnson maintained a Buy rating on REPH, with a price target of $18.00, which implies an upside of 142% from current levels.

Continental Resources is down -10.6% in midday trading to $8.52. Shares opened today at $9.53. The company has a 52-week low of $6.92 and a 52-week high of $52.04. On the Street’s front, the average 12-month analyst price target for the stock is $15.70, marking a 64.74% potential upside from current levels. In a report issued on March 25, Piper Sandler analyst Mark Lear downgraded CLR to Hold, with a price target of $3.00, which reflects a potential downside of -69% from last closing price. Separately, on March 16, RBC’s Brad Heffern maintained a Buy rating on the stock and has a price target of $14.00. In the last 30 days, insiders purchased $1.18M worth of CLR shares. Over the last 3 months, the insider sentiment on Continental Resources has been positive based on 32 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.